@RA_86_99 and
@Glyco,
I cannot agree more with you guys.
I have met Yacov, the board of directors and senior management at least a couple of times, and got a great impression not just because of their track record (e.g. Lifewatch AG) but also for the vision and the goals they have for GMed. GMed is Yacov's legacy, the "G" in GMed is due to his surname (Geva) and is his "baby".
Checking my notes from the pre-IPO times, Dr Kenneth Melanie, chairman (considered one of the most powerful CEO's in the health-insurance Business in USA), mentioned that he was extremely impressed with Yacov's team and how they were able to stay profitable while insurance companies were trying to pressure him to reduce costs and margins.
In my very personal opinion the current share price should be not less than 45c, I think current price has been discounted at an extremely high risk factor, it seems like the market still doesn't believe the GMV's story for different reasons, some of them valid (e.g. China is high risk, contracts not being served yet..... "happy" the troll has an extensive list) and others not (e.g. Yacov mortgaging his shares.... under ASX rules he cannot, who ever started this rumour is totally ignorant of ASX regulations, also check for "happy" the troll, he has an extensive list of inaccurate info). My point is that when GMV gets the CFDA approval and start showing evidence of the existence of the contracts then the SP should move quickly and catch up (e.g. RAP was valued at more than $200m at some point and they didn't even had a product/service to sell... and they still don't)
I have a fair amount of shares, being since pre-IPO, top up significanly when it went under 15, bought few mid 20's, sold few at 55c plus, and being buying more in the early 30's recently. I always like to mention that investors should manage their risk and not over-expose themselves.
Cheers,
Rod
